Actinium Pharmaceuticals (ATNM) Q2 2025 earnings summary

Executive summary

• Focused on developing targeted radiotherapies for advanced cancers, with a pipeline spanning hematology, solid tumors, and conditioning for cell/gene therapies.

• Strategic prioritization toward solid tumor programs, notably ATNM-400 for prostate cancer and Actimab-A in combination with PD-1 inhibitors for solid tumors.

• Workforce optimization reduced headcount by 14% in Q2 2025; CMO resigned with no operational impact expected.

• No commercial revenue; operations funded by prior equity raises and upfront licensing payments.

Financial highlights

• Net loss for Q2 2025 was $6.9M, down from $11.4M in Q2 2024, driven by lower R&D and G&A expenses.

• Net loss for the six months ended June 30, 2025 was $22.8M, up from $20.0M in the prior-year period, due to higher non-cash stock-based compensation.

• R&D expenses for Q2 2025 were $4.9M, down $3.9M year-over-year; G&A expenses were $2.6M, down $1.0M.

• Cash and equivalents at June 30, 2025 were $59.9M, compared to $72.9M at December 31, 2024.

• No shares sold in H1 2025; $24.7M net proceeds from equity sales in H1 2024.

Outlook and guidance

• Existing resources expected to fund operations for more than 12 months from the report date.

• Actively seeking a strategic partner for Iomab-B in the U.S. to execute required FDA trials.

• Initial proof-of-concept data for Actimab-A/PD-1 inhibitor solid tumor trials expected in H1 2026.